{"url_path":"/sec/hcwb/8-k/2026-06-15/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote of Security Holders.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-15","source_url":"https://www.sec.gov/Archives/edgar/data/1828673/0001493152-26-028699-index.html","accession_number":"0001493152-26-028699","cik":"0001828673","ticker":"HCWB","issuer_name":"HCW Biologics Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1828673/0001493152-26-028699-index.html","primary_entity_key":"0001828673","primary_entity_name":"HCW Biologics Inc."},"word_count":472,"has_tables":true,"body_markdown":"**Item\n5.07 Submission of Matters to a Vote of Security Holders.**\n\n \n\nOn\nJune 15, 2026, HCW Biologics Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”).\nAt the Annual Meeting, the stockholders voted on the following five proposals and cast their votes as follows:\n\n \n\n1.The\nCompany’s stockholders elected the persons listed below as Class II directors listed\nin the accompanying proxy statement to serve a three-year term expiring at the 2029 annual\nmeeting of stockholders and until such director’s successor is duly elected and qualified\nor until such director’s earlier death, resignation, disqualification or removal.\n\n \n\nNominee \nFor  \nWithheld  \nBroker Non-Votes \n\nLisa M. Giles \n1,127,580  \n230,984  \n1,189,957 \n\nRick S. Greene \n1,128,039  \n230,525  \n1,189,957 \n\n \n\n2.The\nCompany’s stockholders ratified the appointment of Crowe LLP as the independent registered\npublic accounting firm of the Company for the fiscal year ending December 31, 2026.\n\n \n\nFor \nAgainst \nAbstain \nBroker Non-Votes\n\n2,536,919 \n1,748 \n9,854 \n—\n\n \n\n3.The\nCompany’s stockholders approved an amendment to the Company’s certificate of\nincorporation on or before the one (1) year anniversary of the Annual Meeting, to implement\none or more reverse stock splits of the outstanding shares of the Company’s common\nstock, par value $0.0001 per share (our “Common Stock”) (as necessary to maintain\na listing of our Common Stock on The Nasdaq Stock Market LLC (“Nasdaq”)) in an\naggregate range from one-for-five (1:5) up to one-for-twenty (1:20).\n\n \n\nFor \nAgainst \nAbstain \nBroker Non-Votes\n\n2,231,771 \n258,125 \n58,625 \n—\n\n \n\n4.The\nCompany’s stockholders approved, for purposes of complying with Nasdaq Listing Rule\n5635(d), the issuance of shares of our Common Stock upon exercise of up to 2,477,292 Common\nStock Purchase Warrants (the “Common Warrants”) issued pursuant to that certain\nSecurities Purchase Agreement, dated February 17, 2026, entered into in connection with the\nCompany’s follow-on public offering of Units, consisting of one share of Common Stock\npurchased for $0.6055 and one Common Warrant which may be exercised to purchase one share\nof Common Stock for $0.6055 per share..\n\n \n\nFor \nAgainst \nAbstain \nBroker Non-Votes\n\n1,102,910 \n233,136 \n22,518 \n1,189,957\n\n \n\n5.The\nCompany’s stockholders approved, for purposes of complying with Nasdaq Listing Rule\n5635(d), the repricing of certain warrants issued on November 20, 2025 to purchase up to\n3,020,410 shares of our Common Stock pursuant to that certain Existing Warrants Amendment\nAgreement, dated February 17, 2026, to reduce the exercise price of the Existing Warrants\nto $0.6055 per share, and to approve the issuance of shares of our Common Stock upon exercise\nof the Existing Warrants as so amended.\n\n \n\nFor \nAgainst \nAbstain \nBroker Non-Votes\n\n1,083,864 \n251,605 \n23,095 \n1,189,957\n\n \n\n \n\n \n\n \n\n**SIGNATURES**\n\n** **\n\nPursuant\nto the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by\nthe undersigned hereunto duly authorized.\n\n \n\n \n**HCW BIOLOGICS INC.**\n\n \n \n \n\nDate:\nJune 15, 2026\nBy:\n*/s/\nHing C. Wong*\n\n \n \nHing\nC. Wong, Founder and Chief Executive Officer"}